INSM-18
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201562

CAS#: 500-38-9

Description: INSM-18 is a bioactive chemical.


Price and Availability

Size
Price

1g
USD 300
Size
Price

5g
USD 780
Size
Price

INSM-18, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 201562
Name: INSM-18
CAS#: 500-38-9
Chemical Formula: C18H22O4
Exact Mass: 302.15181
Molecular Weight: 302.36488
Elemental Analysis: C, 71.50; H, 7.33; O, 21.17


Synonym: INSM18; INSM-18, INSM 18, nordihydroguaiaretic acid; NDGA

IUPAC/Chemical Name: 4,4'-((2R,3S)-2,3-dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)

InChi Key: HCZKYJDFEPMADG-TXEJJXNPSA-N

InChi Code: InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+

SMILES Code: C[C@@H](CC1=CC=C(O)C(O)=C1)[C@H](C)CC2=CC=C(O)C(O)=C2


Technical Data

Appearance:
Solid powder

Purity:
>98%

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

INSM-18 is an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor (Her2/Neu). It has demonstrated anti-tumor activity in preclinical studies of breast, lung, pancreatic and prostate tumors. Two single dose Phase I clinical studies in healthy volunteers have been previously completed with INSM-18. In both studies, INSM-18 was safe and well tolerated.
 
Current developer:    Insmed.
 
 


References

1: Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as  a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011 Sep 15;344(1-2):1-24. Epub 2011 Jul 18. PubMed PMID: 21782884.